Business Context and Reporting Period
Company: Aprea Therapeutics, Inc. (APRE)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Year ended December 31, 2025
Business Overview: Aprea is a clinical-stage precision medicine oncology company focused on synthetic lethality-based cancer therapeutics. The company has no commercial products and generates no product revenue. Its primary assets are two clinical-stage product candidates: APR-1051 (WEE1 inhibitor) and ATRN-119 (ATR inhibitor). The company is classified as a "smaller reporting company."
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Grant Revenue | $0.3 million | $1.5 million |
| Net Loss | $(12.6) million | $(13.0) million |
| Research & Development Expenses | $7.0 million | $9.4 million |
| General & Administrative Expenses | $6.5 million | $6.5 million |
| Cash and Cash Equivalents (Year End) | $14.6 million | $22.8 million |
| Accumulated Deficit | $(333.6) million | $(321.0) million |
| Net Cash Used in Operating Activities | $(12.9) million | $(13.6) million |
Note: The filing text does not provide specific data on debt, margins, or liquidity ratios beyond cash balances and operating cash flow.
Material Changes vs. Prior Period
- Revenue Decline: Grant revenue decreased by approximately $1.2 million (81%) due to reduced recognition of NIH grant revenue.
- Expense Reduction: Total operating expenses decreased by $2.3 million. R&D expenses dropped primarily due to a voluntary pause in the monotherapy arms of the ATRN-119 clinical trial (ABOYA-119) and reduced costs for the APR-1051 trial.
- Cash Burn: Cash and cash equivalents decreased by approximately $8.2 million year-over-year, reflecting continued operating losses despite reduced expenses.
- Financing Activity: The company raised approximately $4.6 million in net cash from financing activities in 2025, primarily through private placements and at-the-market stock sales, compared to $14.8 million in 2024.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Going Concern: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for at least 12 months from the filing date. The company expects its cash on hand ($14.6 million) plus proceeds from a January 2026 private placement ($5.6 million) to fund operations only into the first quarter of 2027.
- Strategic Pivot: The company has paused monotherapy enrollment for ATRN-119 to focus on combination therapy approaches (e.g., with radiation, ADCs, or immune checkpoint inhibitors).
- Clinical Milestones:
- APR-1051: Phase 1 dose-escalation is ongoing. Two unconfirmed partial responses were observed in patients with PPP2R1A-mutated endometrial cancer. Dose-escalation is expected to complete in Q3 2026.
- ATRN-119: Recommended Phase 2 dose (RP2D) of 1,100 mg was determined in October 2025. Development is shifting toward combination studies.
Risks and Contingencies
- Liquidity Risk: The company requires substantial additional funding to continue operations. Failure to secure financing could force delays, reductions, or elimination of R&D programs.
- Listing Compliance: On January 23, 2026, the company received a deficiency letter from Nasdaq regarding its stock price falling below the $1.00 minimum bid price requirement. The company has 180 days to regain compliance or face delisting.
- Development Risk: As a clinical-stage company with no approved products, success depends entirely on the clinical performance of APR-1051 and ATRN-119. Early clinical results are not predictive of later-stage success.
- Supply Chain: The company relies on third-party manufacturers, including a supplier in China, exposing it to geopolitical risks and tariffs.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $5.6 million raised in January 2026 and the timeline for the next required financing round to avoid operational disruption.
- Nasdaq Compliance: Monitor the company's progress in regaining compliance with the $1.00 minimum bid price requirement to avoid delisting.
- Clinical Data: Review upcoming data readouts for APR-1051 (expected Q2/Q3 2026) to confirm the durability of the observed partial responses and safety profile.
- Strategic Execution: Assess the progress of the strategic pivot for ATRN-119 from monotherapy to combination therapies and the timeline for initiating new combination trials.
- Going Concern Status: Evaluate the auditor's "going concern" qualification and the specific plans management has outlined to secure long-term funding.